APA (7th ed.) Citation

Rui Xiong, Jing Lei, Sicen Pan, Hong Zhang, Yongtao Tong, Wei Wu, . . . Xiaodan Lai. (2023). Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Rui Xiong, Jing Lei, Sicen Pan, Hong Zhang, Yongtao Tong, Wei Wu, Yi Huang, and Xiaodan Lai. Post-marketing Safety Surveillance of Dalfampridine for Multiple Sclerosis Using FDA Adverse Event Reporting System. Frontiers Media S.A., 2023.

MLA (9th ed.) Citation

Rui Xiong, et al. Post-marketing Safety Surveillance of Dalfampridine for Multiple Sclerosis Using FDA Adverse Event Reporting System. Frontiers Media S.A., 2023.